MarginsXMarginsX
Home › Markets › Health Care › PRFX

PRF Technologies Ltd. (PRFX)

PRFX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.6948
-11.22% on the day
Market cap
$2.4M
Nano cap
Revenue · 2025
$17K
Prior year not contiguous
Net income · 2025
-$5.0M
-29541.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1801834/000117891326001782/0001178913-26-001782-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPRFX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO year2020
SEC CIK0001801834
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$17K
Net income-$5.0M
Operating income-$5.1M
Net margin-29541.2%
Operating margin-30129.4%
Revenue growthNo prior-year revenue to compare
Cash$3.1M
Total assets$12.0M
P/E (computed)Net income was not positive
P/S (computed)143.0×

Warning signs

Cash runway
9.5 months
$3.1M cash at December 31, 2025
Share count, 1 year
+182.3%
2024-12-31 to 2025-12-31 · +2243.2% over 3 years
Going-concern doubt
Yes
20-F filed March 26, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Therefore, there is substantial doubt about our ability to continue as a going concern."
20-F 2026-03-26
Cash and burn$3.1M cash; operating cash flow -$989K a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 years2; latest 1-for-5 on 2026-02-06Source 2026-02-06
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-04-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$17K-$5.0M-$4.0M$3.1MNo debt tags$17K20-F 2026-03-26
FY 2024
2024-12-31
$0-$14.6M-$12.6M$4.3MNo debt tags$020-F 2026-03-26
FY 2023
2023-12-31
$0-$9.3M-$6.7M$8.0MNo debt tags$020-F 2026-03-26
FY 2022
2022-12-31
Not filed-$8.8M-$6.5M$4.1MNo debt tagsNeeds four quarters20-F 2025-04-07
FY 2021
2021-12-31
Not filed-$7.2M-$6.6M$16.5MNo debt tagsNeeds four quarters20-F 2024-02-29
FY 2020
2020-12-31
Not filed-$4.1M-$2.6M$15.7MNo debt tagsNeeds four quarters20-F 2023-03-15
FY 2019
2019-12-31
Not filed-$1.3M-$609K$941K$14.5MNeeds four quarters20-F 2022-03-16
FY 2018
2018-12-31
Not filed-$828K-$635K$46K$3.7MNeeds four quarters20-F 2021-03-18

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-09-03
Latest annual report20-F2026-03-26
Latest quarterly / interim6-K2026-11-13

Source: SEC EDGAR submissions feed, 265 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.1%
1 month-4.3%
3 months-34.7%
Year to date-75.6%
1 year-83.2%
From 52-week high-86.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GNPXGenprex Inc.$1.90-8.65%$2.5M
REVBRevelation Biosciences Inc.$3.82-10.43%$2.6M
EOCNEocene Ltd.$2.53+5.86%$2.6M
JUNSJupiter Neurosciences Inc.$1.70-8.11%$2.2M
PPBTPurple Biotech Ltd.$1.68+3.70%$2.7M
DCOYDecoy Therapeutics Inc.$0.9010-7.61%$2.1M
SBFMSunshine Biopharma Inc.$2.60-3.70%$2.1M
CMNDClearmind Medicine Inc. Common Shares$4.18-7.67%$2.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier